Table of Contents
ISRN Pharmacology
Volume 2013, Article ID 352865, 5 pages
Review Article

The Pharmacological Options in the Treatment of Eating Disorders

1Mental Health Unit, District 24, ASL Napoli 1 Centro, Molosiglio, Via Acton, 80145 Napoli, Italy
2Department of Pharmacy, University of Salerno, Via Ponte Don Melillo, 84084 Fisciano, Salerno, Italy

Received 10 May 2013; Accepted 18 June 2013

Academic Editors: A. Fernandez-Guasti and J.-A. Mico

Copyright © 2013 W. Milano et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


The eating disorders (DCA) are complex systemic diseases with high social impact, which tend to become chronic with significant medical and psychiatric comorbidities. The literature data showed that there is good evidence to suggest the use of SSRIs, particularly at high doses of fluoxetine, in the treatment of BN reducing both the crisis of binge that the phenomena compensates and reducing the episodes of binge in patients with BED in the short term. Also, the topiramate (an AED) showed a good effectiveness in reducing the frequency and magnitude of episodes of binge with body weight reduction, both in the BN that is in the therapy of BED. To date, modest data support the use of low doses of second-generation antipsychotics in an attempt to reduce the creation of polarized weight and body shapes, the obsessive component, and anxiety in patients with AN. Data in the literature on long-term drug treatment of eating disorders are still very modest. It is essential to remember that the pharmacotherapy has, however, a remarkable efficacy in treating psychiatric disorders that occur in comorbidity with eating disorders, such as mood disorders, anxiety, insomnia, and obsessive-compulsive personality disorders and behavior.